Distinction of AA vs inherited BM failure syndromes

Naveen Pemmaraju shared on X:

“Our article just out in Clinical Lymphoma Myeloma Leukemia (CLML) led by Dr Patrice Nasnason on the Detection of PNH clones that can aid in distinction of AA vs inherited BM failure syndromes.”

Source: Naveen Pemmaraju/X

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network.

He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature

Authors: Patrice Nasnas, Jianhua Ling, Yoheved Gerstein, Sa A. Wang, Sanam Loghavi, Danielle Hammond, Guillermo Montalban-Bravo, Jayastu Senapati, Naveen Pemmaraju, Jessie Corredor, Sherry Pierce, Michael Roth, Farhad Ravandi, Branko Cuglievan, Tapan Kadia and Courtney D. DiNardo